Ifrah Financial Services Inc. Purchases 19,654 Shares of Exelixis, Inc. $EXEL

Ifrah Financial Services Inc. purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) in the third quarter, Holdings Channel reports. The firm purchased 19,654 shares of the biotechnology company’s stock, valued at approximately $1,148,000.

Several other institutional investors have also recently bought and sold shares of EXEL. B. Riley Wealth Advisors Inc. acquired a new position in shares of Exelixis during the third quarter valued at about $329,000. Wedmont Private Capital increased its position in shares of Exelixis by 7.2% during the third quarter. Wedmont Private Capital now owns 8,940 shares of the biotechnology company’s stock worth $528,000 after acquiring an additional 598 shares in the last quarter. Monument Capital Management raised its holdings in shares of Exelixis by 1.3% in the 3rd quarter. Monument Capital Management now owns 82,041 shares of the biotechnology company’s stock worth $4,792,000 after acquiring an additional 1,052 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Exelixis by 10.9% in the 3rd quarter. GAMMA Investing LLC now owns 12,227 shares of the biotechnology company’s stock worth $714,000 after acquiring an additional 1,202 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in shares of Exelixis by 29.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 18,290 shares of the biotechnology company’s stock worth $1,068,000 after acquiring an additional 4,119 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Trading Down 0.5%

Shares of NASDAQ:EXEL opened at $59.51 on Wednesday. The stock has a market cap of $14.75 billion, a PE ratio of 18.71, a price-to-earnings-growth ratio of 1.68 and a beta of 0.47. The stock’s fifty day simple moving average is $56.43 and its two-hundred day simple moving average is $52.53. Exelixis, Inc. has a 1-year low of $33.76 and a 1-year high of $61.66.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.06. Exelixis had a net margin of 35.33% and a return on equity of 42.17%. The firm had revenue of $628.69 million during the quarter, compared to analyst estimates of $636.40 million. During the same quarter in the prior year, the business posted $0.75 EPS. The business’s revenue was up 10.6% compared to the same quarter last year. On average, sell-side analysts forecast that Exelixis, Inc. will post 3.19 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

EXEL has been the topic of several recent research reports. Citigroup reaffirmed a “market outperform” rating on shares of Exelixis in a research report on Monday, September 14th. Wells Fargo & Company boosted their price objective on Exelixis from $40.00 to $49.00 and gave the stock an “equal weight” rating in a report on Monday, July 13th. Wall Street Zen lowered Exelixis from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Royal Bank Of Canada increased their price objective on Exelixis from $45.00 to $51.00 and gave the stock a “sector perform” rating in a research note on Friday. Finally, William Blair reissued an “outperform” rating on shares of Exelixis in a research note on Friday, September 11th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $50.79.

Insider Buying and Selling at Exelixis

In related news, Director Mary Beckerle sold 9,812 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $53.66, for a total transaction of $526,511.92. Following the transaction, the director directly owned 16,079 shares of the company’s stock, valued at $862,799.14. This trade represents a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.60% of the stock is owned by insiders.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer. The company’s research and development activities are centered primarily on targeted therapies and other treatments for solid tumors.

Exelixis’ principal product is cabozantinib, marketed in the United States as CABOMETYX tablets for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. The company also markets COMETRIQ, a cabozantinib formulation approved in the United States for progressive or metastatic medullary thyroid cancer.

Exelixis was founded in 1994 and is headquartered in Alameda, California.